BAUSCH HEALTH COMPANIES INC.

ISIN: CA0717341071 WKN: 071734107 Asset Class: Stock



Company Profile

Total assets

Tax Expense Rate

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

Financial figures, Fiscal year: from 01.01. to 31.12. 2023 2022 2021 **Financial figures** Assets Liabilities and equity Assets Liabilities and equity Assets Liabilities and equity **Current assets** 7.378.885.000 7.082.482.000 5.754.472.000 Common stock capital 13.743.767.000 13.031.918.000 14.079.285.000 **Fixed assets** 28 684 824 000 29 048 773 000 29 804 024 000 Equity capital of a company -108,125,000 352,287,000 -42,947,000 1.268.493.000 800,775,000 2,676,614,000 Cash and cash equivalents **Accrued liabilities** 0 0 0 Other assets **Current liabilities** 5.672.617.000 5.339.857.000 6.565.853.000 Prepayments and accrued income Non-current liabilities 30.499.218.000 29.111.100.000 30.363.599.000 Different income Other liabilities 1,161,686,000 1.036.536.000 809.679.000

Balance notes			
	2023	2022	2021
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	20,270	19,900	19,100
Equity ratio	3.14%	4.72%	0.13%
Debt-equity ratio	3,087.65%	2,019.31%	76,747.37%
Others			

36.063.710.000

34.803.245.000

2023

-56.67%

36.886.506.000

2022

-64.34%

34.803.245.000

36.063.710.000

2021

8.50%

36.886.506.000

BAUSCH HEALTH COMPANIES INC.

ISIN: CA0717341071 WKN: 071734107 Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	11,819,208,000	10,576,257,000	10,573,980,000
Net income	-799,014,000	-292,917,000	-1,188,538,000
EBIT	877,374,674	1,194,090,092	377,237,490
Operating income before taxes	-526,377,000	-167,939,000	-1,283,822,000
Cash Flow	1,344,288,000	-1,040,180,000	1,727,643,000
Net interest income	-1,853,120,000	-1,973,609,000	-1,854,270,000
Research and development expenses	815,210,000	688,680,000	582,985,000
Income taxes	298,280,000	108,053,000	-109,074,000
Result from investments in subsidaries, associates and other	0	0	0
Revenues per employee	385,597	351,461	366,103

Board of Directors		
John Paulson	Chairman of Supervisory Board	
Amy Wechsler	Member of Supervisory Board	
Richard Mulligan	Member of Supervisory Board	
Brett Icahn	Member of Supervisory Board	
Christian Garcia	Member of Supervisory Board	
Frank Lee	Member of Supervisory Board	
Robert Power	Member of Supervisory Board	
Sarah Kavanagh	Member of Supervisory Board	
Steven Miller	Member of Supervisory Board	

Members of Management Board			
Thomas Appio	Chairman of Managing Board		
Tage Ramakrishna	Member of Executive Committee		
Cees Heiman	Member of Executive Committee		
Fernando Zarate	Member of Executive Committee		
Graham Jackson	Member of Executive Committee		
Jeff Hartness	Member of Executive Committee		
Kathleen Fitzpatrick	Member of Executive Committee		
Mirza Dautbegovic	Member of Executive Committee		
Seana Carson	Member of Executive Committee		
Tom Vadaketh	Member of Executive Committee		